vialroom

#dosing-titration 2025-09-26

Friday15 messages6 participantstimes are UTC
Highlights from this day
  • VialBot — On this day 4 years ago this channel logged 109 messages. 16:35
  • secretagogue_sy — how do you decide between holding and stepping when both feel wrong 16:43
  • secretagogue_sy — slightly off topic but came down from a treatment dose to maintenance over about three months and it was uneventful 16:44
  • food_noise_off — the argument for splitting is a flatter curve. the argument against is you have doubled your injections for a guess 16:55
  • VialBot — Testing queue: 8 submissions open, 97 awaiting dispatch. 17:32
TA

you do not have to escalate at all. that is a real option that gets forgotten

TA

update on the earlier thing what does the room think about jumping a rung to catch up

i log dose, day, weight and one line about how the week felt. thats enough to make decisions on

VB

On this day 4 years ago this channel logged 109 messages.

SS

how do you decide between holding and stepping when both feel wrong

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

slightly off topic but came down from a treatment dose to maintenance over about three months and it was uneventful

🔥5

whats your rule for when a side effect means hold rather than push

*Medutest not the other one

AA

update from 15 months ago: held at the same dose the whole time and still losing slowly

is week 8 too early to be thinking about the next step

FN

the argument for splitting is a flatter curve. the argument against is you have doubled your injections for a guess

AA

follow up whats a sensible maintenance dose after a year at treatment dose

FN

the ladder in the trials is a starting point, not a schedule you owe anyone

VB

Testing queue: 8 submissions open, 97 awaiting dispatch.